Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SWKH
SWKH logo

SWKH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SWK Holdings Corp (SWKH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
--
1 Day change
-5.22%
52 Week Range
17.900
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

SWK Holdings Corp (SWKH) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is significantly deteriorating, with revenue, net income, and EPS showing sharp declines. Technical indicators suggest a bearish trend, and there are no positive trading signals or catalysts to support a buy decision. Additionally, there is no recent news, analyst ratings, or insider activity to indicate potential upside.

Technical Analysis

The MACD histogram is negative and expanding, indicating a bearish momentum. The RSI is at 21.401, which is in the neutral zone but close to oversold territory. Moving averages are converging, showing no clear trend. Support and resistance levels suggest limited upside potential with key support at 15.609 and resistance at 17.185. Overall, the technical indicators point to a bearish or neutral outlook.

Positive Catalysts

  • NULL identified. No recent news, analyst upgrades, or insider activity to suggest positive momentum.

Neutral/Negative Catalysts

  • Significant decline in financial performance in Q4 2025, with revenue down 29.70% YoY, net income down 430.18% YoY, and EPS down 433.33% YoY. Technical indicators show bearish momentum, and there is a 60% chance of further price decline in the short term.

Financial Performance

In Q4 2025, revenue dropped to $8.69M (-29.70% YoY), net income dropped to -$19.39M (-430.18% YoY), and EPS dropped to -1.6 (-433.33% YoY). Gross margin remained flat at 100%. Overall, the financials indicate a significant deterioration in the company's performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast SWKH stock price to rise
Analyst Rating
0
Wall Street analysts forecast SWKH stock price to rise
Buy
Hold
Sell
0
Current: 15.900
sliders
Low
0
Averages
0
High
0
0
Current: 15.900
sliders
Low
0
Averages
0
High
0
Maxim
Maxim
Buy
downgrade
$21 -> $18
AI Analysis
2025-05-19
Reason
Maxim
Maxim
Price Target
$21 -> $18
AI Analysis
2025-05-19
downgrade
Buy
Reason
Maxim lowered the firm's price target on SWK Holdings to $18 from $21 and keeps a Buy rating on the shares. The tangible book value on the stock is down after the company's sale of its pharma royalty portfolio and the payout of its $4 per share special dividend, the analyst tells investors in a research note.

People Also Watch